Yatharth Hospital operates a network of multi-specialty tertiary and quaternary care hospitals across the NCR and North India, with 2,555 beds as of Q1 FY27, spread across clusters in Noida, Faridabad, Delhi, Agra, and Jhansi. The company earns revenue from bed occupancy, surgeries, and super-specialty procedures, with oncology at roughly 10% of revenue and a payer mix that is about 35% government schemes, the rest private insurance and cash. The competitive structure is favorable: it is the largest player in its core micro-markets, with established hospitals like Noida and Jhansi running at 86-90% occupancy, and new premium facilities like New Delhi and Faridabad Sector 20 commanding ARPOB above INR 36,000-40,000 versus the group average of INR 33,700. Reported EBITDA margin in Q1 FY27 was 23.3%, but adjusted for new-hospital drag it was 28.1%, and mature hospitals alone run at 28-29%, illustrating the quality of the underlying business.
The economics persist because of doctor retention (senior attrition only 3-4%, overall 7%), cluster-wise dominance, and the ability to turn assets around quickly. The company has demonstrated this repeatedly: Faridabad Sector 20 reached EBITDA breakeven in 9 months versus a 12-14 month target, and the acquired Agra hospital delivered a 20%+ EBITDA margin in its first full quarter. The exclusive partnership with Noida International Airport (Jewar) adds a medical-travel supply line that typically yields ARPOB 45-55% higher than domestic. These factors—clinician loyalty, micro-market dominance, and a proven M&A playbook—are difficult to replicate, as a new entrant would need years of physician recruitment, brand building, and capital.
The inflection is the current capacity expansion. Management is executing a plan to reach 5,000 beds in under three years, with over 3,200 announced beds already including the under-construction Gurugram hospital (operational by April 2027) and brownfield expansions at Noida Extension and Greater Noida (commissioned in about 15-18 months). Within 18-24 months from now, by the middle of 2028, the company will have Gurugram in its ramp-up phase (ARPOB exceeding INR 50,000), the brownfield additions of 450 beds operational, and the new Delhi and Faridabad hospitals well past breakeven, contributing at 15-20% EBITDA margins as they approach mature occupancy. Oncology share should rise to 15% of the specialty mix within 1.5-2 years, and the government payer mix should drop to roughly 25-28%, lifting blended ARPOB. The resulting revenue growth is guided to surpass the prior year's 37% YoY, with EBITDA margins moving toward 26-27% as new hospitals mature.
Management has consistently under-promised and over-delivered. In Nov 2025, they guided 30%+ revenue growth for FY26; by Q3 FY26 actual growth was 46% YoY. They guided EBITDA margins of around 24% for FY26; the adjusted margin in Q3 was 29.2% (excluding new-hospital drag), and the FY26 reported margin came in at 24.2% despite heavy drag. The acquisition of Agra was completed ahead of schedule and was EBITDA-positive from day one. Capital allocation is disciplined: the 5,000-bed plan is funded via internal accruals and manageable debt—currently total debt is around INR 300 crore against net cash of over INR 1,160 crore as of FY26—with no equity dilution planned. Guidance for FY27 is for revenue growth exceeding 36% YoY and EBITDA margins at 24-25%, which the company expects to improve as new hospitals contribute.
The earnings path is quantifiable: Q1 FY27 EBITDA was INR 917 million (23.3% margin), and with mature hospitals at 28-29% margins and new ones ramping, blended margins should rise to 26-27% within two years, driving profit growth ahead of revenue. The key assumptions are that Gurugram opens on time, the brownfield expansions complete within 15-18 months, and the new Delhi and Faridabad hospitals reach 60%+ occupancy. The primary falsifier is a delay in the ramp-up of these assets, as evidenced by the still-modest occupancies (New Delhi 49%, Noida Extension 56% as of Q1 FY27), or a government rate capping that compresses ARPOB. Further, the company expects to add at least one more hospital acquisition in FY27, which could add short-term drag. However, given the management's track record of beating guidance and the structural tailwinds from CGHS rate revisions (5% revenue benefit) and medical-value travel, the risk-reward is favorable.
companyname: Yatharth Hospital & Trauma Care Services Limited ticker: YATHARTH sector: Healthcare – Hospitals / Tertiary & Quaternary Care Yatharth Hospital & Trauma Care Services Limited, incorporated in 2008 and headquartered in Noida, operates a chain of multi-specialty hospitals across Delhi NCR, Jhansi-Orchha in Madhya Pradesh, and since February 2026, Agra in Uttar Pradesh. The company started with a single hospital in Greater Noida in 2010 and has expanded through a mix of greenfield con...
Read the full report →capex, margin expansion, geographic expansion, acquisition inorganic
FY27 revenue growth guided to surpass 36% YoY driven by new capacity ramp-up and operational efficiencies
Guidance upgradedoverdeliver
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Yatharth Hospital & Trauma Care Services Limited and 4,900+ companies.
5-day free pass. No card required.